Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer
ConclusionsPatients with somatic co-mutation ofTP53 andPIK3CA were associated with unfavorable survival compared with non-carriers. Co-mutation ofTP53 andPIK3CA could be used as a potential prognosis marker in post-neoadjuvant chemotherapy breast cancer patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy